Latest updates for Inclisiran

Fresh curated links around inclisiran are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Recent items include:

  • Lilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitors
  • Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder
  • Intellia races in vivo CRISPR therapy to FDA after phase 3 data paint ‘compelling’ picture

Post angles to try

Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

fiercebiotech.com /1 week ago

Lilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitors

Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it picked up from Verve Therapeutics, with the candidate now showing strong and consistent...

Read source
biopharmadive.com /1 month ago

Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder

The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of intense investor debate...

Read source
fiercebiotech.com /1 month ago

Intellia races in vivo CRISPR therapy to FDA after phase 3 data paint ‘compelling’ picture

A phase 3 trial of Intellia Therapeutics’ in vivo gene editing therapy lonvoguran ziclumeran has hit its primary endpoint, leading the biotech to start a rolling submission for FDA...

Read source
medcitynews.com /1 month ago

Intellia’s Data Reveal Tees Up FDA Filing for CRISPR-Based In Vivo Gene-Editing Med

Intellia Therapeutics’ lonvo-z uses CRISPR to inactivate a gene in the liver to reduce levels of a protein key to the swelling attacks from the rare disease hereditary angioedema....

Read source
biopharmadive.com /1 week ago

Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antit...

Read source
nytimes.com /5 days ago

One-and-Done Heart Disease Prevention? Scientists Show It May Be Possible.

A single infusion of an experimental gene-editing drug seemed to reduce LDL long-term in a small trial. The results may point to something “curative,” one expert said.

Read source
fiercebiotech.com /1 month ago

Novartis narrows focus for anticoagulant after failure to best Eliquis in phase 3 trial

A little over a year after reabsorbing its anticoagulant abelacimab, Novartis has now terminated two phase 3 trials for the antibody.

Read source
biopharmadive.com /1 month ago

Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM

Shares of Immunovant, Alto and Oric Pharmaceuticals fell this week on clinical trial updates. Elsewhere, Orca Bio’s cell therapy hit a delay and Korsana entered a reverse merger.

Read source
biopharmadive.com /4 days ago

Early data for heart drug affirm Lilly’s billion-dollar bet on Verve

The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.

Read source
biopharmadive.com /1 month ago

Oruka surges as long-acting psoriasis drug shows early promise

A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently. 

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.

Start creating posts

Sources covering Inclisiran

rss.nytimes.com

Recent coverage from public sources
Public source

medcitynews.com

Recent coverage from public sources
Public source

biopharmadive.com

Recent coverage from public sources
Public source

fiercebiotech.com

Recent coverage from public sources
Public source

Related searches

BioPharma Cholesterol Clinical Trials Eli Lilly and Company FDA Genetic Engineering Genetics and Heredity Heart Intellia Therapeutics Medicine and Health New England Journal of Medicine Pharma

Recent searches

Artificial Intelligence Machine Learning Data Science Data Engineering Business Intelligence Web Development Software Development Software Testing Programming JavaScript DevOps Cyber Security Product Management Project Management Design UX UX Research Graphic Design Video Production Video Editing